Treatment of disease conditions via administration of DNA repair enzyme
The present invention is directed to compositions and methods of preserving viability of islets of Langerhans for transplantation, and treating various diseases and other abnormal or pathological conditions, including inflammatory bowel disease, ischemic heart disease, acute lung injury, acute respiratory distress syndrome and radiation-induced brain injury, with DNA repair enzymes that are directed to the mitochondria.
1. A method of enhancing viability of islets of Langerhans which comprise β-cells for purposes of transplantation, comprising contacting the islets of Langerhans with a composition comprising a multi-domain conjugate comprising, from N-terminus to C-terminus, a mitochondrial localization sequence comprising a manganese Superoxide Dismutase (MNSOD) sequence MLSRAVCGTSRQLAPALGYLGSRQ (SEQ ID NO:1), a DNA repair enzyme comprising human 8-oxoguanine DNA glycosylase (hOGG1) or Endonuclease III (Endo III), and a protein transduction domain comprising a TAT protein having the amino acid sequence YGRKKRRQRRR (SEQ ID NO:8), in an amount effective to enhance viability of the β-cells.
2. The method of claim 1 , comprising administering the composition to a diabetic.
3. The method of claim 2 , wherein the diabetic is a type-I diabetic.
4. The method of claim 3 , comprising administering the composition to the type-I diabetic prior to transplantation of the islets of Langerhans to the diabetic.
5. The method of claim 3 , comprising administering the composition to the type-I diabetic with transplantation of the islets of Langerhans to the diabetic.
6. The method of claim 3 , comprising administering the composition to the type-I diabetic subsequent to transplantation of the islets of Langerhans to the diabetic.
7. The method of claim 2 , wherein the diabetic is a type-II diabetic.
8. The method of claim 1 , comprising administering the composition to a islets of Langerhans donor.
9. The method of claim 1 , comprising introducing the composition into a medium containing islets of Langerhans obtained from a donor.
10. A method of treating oxidative-stress induced damage to mitochondrial DNA, comprising administering to a patient in need thereof, a composition comprising a multi-domain conjugate or fusion protein comprising, from N-terminus to C-terminus, a mitochondrial localization sequence comprising a manganese Superoxide Dismutase (MNSOD) sequence MLSRAVCGTSRQLAPALGYLGSRQ (SEQ ID NO:1), a DNA repair enzyme comprising human 8-oxoguanine DNA glycosylase (hOGG1) or Endo III, and a protein transduction domain comprising a TAT protein having the amino acid sequence YGRKKRRQRRR (SEQ ID NO:8), in a therapeutically effective amount.
11. The method of claim 10 , wherein the patient has Crohn's disease.
12. The method of claim 10 , wherein the patient has ulcerative colitis.
13. The method of claim 10 , wherein the patient has ischemic heart disease.
14. The method of claim 13 , wherein the patient is an obese pre-diabetic.
15. The method of claim 14 , wherein the patient is diabetic.
16. The method of claim 15 , wherein the patient has type II diabetes.
17. The method of claim 10 , wherein the patient has acute lung injury or acute respiratory distress syndrome.
18. The method of claim 17 , wherein the acute lung injury is bronchopulmonary dysplasia.
19. The method of claim 18 , wherein the patient is an infant.
20. The method of claim 10 , wherein the patient has radiation induced-brain injury.
21. The method of claim 1 , wherein the DNA repair enzyme comprises human 8-oxoguanine DNA glycosylase (hOGG1).
22. The method of claim 1 , wherein the DNA repair enzyme comprises Endo III.
23. A composition comprising a culture of islets of Langerhans which comprise β-cells and a multi-domain conjugate comprising, from N-terminus to C-terminus, a mitochondrial localization sequence comprising a manganese Superoxide Dismutase (MNSOD) sequence MLSRAVCGTSRQLAPALGYLGSRQ (SEQ ID NO:1), a DNA repair enzyme comprising human 8-oxoguanine DNA glycosylase (hOGG1) or Endo III, and a protein transduction domain comprising a TAT protein having the amino acid sequence YGRKKRRQRRR (SEQ ID NO:8), in an amount effective to enhance viability of the β-cells.
24. A composition for inhibiting damage to mitochondrial DNA, comprising a multi-domain conjugate or fusion protein comprising, from N-terminus to C-terminus, a mitochondrial targeting sequence comprising a manganese Superoxide Dismutase (MNSOD) sequence MLSRAVCGTSRQLAPALGYLGSRQ (SEQ ID NO:1), a DNA repair enzyme comprising human 8-oxoguanine DNA glycosylase (hOGG1) or Endo III, and a protein transduction domain comprising a TAT protein having the amino acid sequence YGRKKRRQRRR (SEQ ID NO:8), in a therapeutically effective amount, and a pharmaceutically acceptable carrier.
25. The composition of claim 24 , wherein the DNA repair enzyme comprises human 8-oxoguanine DNA glycosylase (hOGG1).
26. The composition of claim 24 , wherein the DNA repair enzyme comprises Endo III.
27. A fusion protein, comprising, from N-terminus to C-terminus, a mitochondrial targeting sequence comprising a manganese Superoxide Dismutase (MNSOD) sequence MLSRAVCGTSRQLAPALGYLGSRQ (SEQ ID NO:1), a DNA repair enzyme comprising human 8-oxoguanine DNA glycosylase (hOGG1), and a protein transduction domain comprising a TAT protein having the amino acid sequence YGRKKRRQRRR (SEQ ID NO:8).
28. A fusion protein, comprising, from N-terminus to C-terminus, a mitochondrial targeting sequence comprising a manganese Superoxide Dismutase (MNSOD) sequence MLSRAVCGTSRQLAPALGYLGSRQ (SEQ ID NO:1), a DNA repair enzyme comprising Endo III, and a protein transduction domain comprising a TAT protein having the amino acid sequence YGRKKRRQRRR (SEQ ID NO:8).